TransMedics Group (TMDX) Projected to Post Earnings on Thursday

Key Points

• TransMedics Group is expected to report Q3 2026 results after Thursday’s market close. Analysts forecast earnings of $0.30 per share and revenue of approximately $178.05 million.
• In its previous quarter, the company earned $0.44 per share, below estimates, but revenue reached $189.95 million and rose 20.7% year over year.
• The stock has declined sharply from its 52-week high of $156 to about $66.90. Analysts have a consensus “Hold” rating and an average price target of $115.60, while recent recommendations range from “Strong Sell” to “Buy.”

TransMedics Group (NASDAQ:TMDX - Get Free Report) is projected to post its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect TransMedics Group to post earnings of $0.2976 per share and revenue of $178.05 million for the quarter. Investors are encouraged to explore the company's upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported $0.44 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.06). TransMedics Group had a net margin of 22.69% and a return on equity of 15.88%. The firm had revenue of $189.95 million for the quarter, compared to analyst estimates of $184.00 million. During the same quarter in the prior year, the business posted $0.92 EPS. The firm's quarterly revenue was up 20.7% compared to the same quarter last year. On average, analysts expect TransMedics Group to post $1.46 EPS for the current fiscal year and $2.26 EPS for the next fiscal year.

TransMedics Group Price Performance

TransMedics Group stock opened at $66.90 on Thursday. The company's fifty day moving average price is $82.69 and its 200 day moving average price is $95.61. TransMedics Group has a 1 year low of $60.10 and a 1 year high of $156.00. The company has a debt-to-equity ratio of 1.62, a quick ratio of 6.07 and a current ratio of 6.62. The stock has a market capitalization of $2.31 billion, a P/E ratio of 17.20, a P/E/G ratio of 0.97 and a beta of 1.94.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. Needham & Company LLC restated a "buy" rating on shares of TransMedics Group in a report on Friday, September 11th. Piper Sandler reissued an "overweight" rating and set a $100.00 target price (down from $120.00) on shares of TransMedics Group in a research note on Wednesday, August 5th. Zacks Research lowered shares of TransMedics Group from a "hold" rating to a "strong sell" rating in a research note on Monday, July 6th. Weiss Ratings raised shares of TransMedics Group from a "hold (c-)" rating to a "hold (c)" rating in a research note on Monday, August 31st. Finally, TD Cowen reiterated a "buy" rating and issued a $120.00 target price on shares of TransMedics Group in a report on Tuesday, September 8th. Five research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $115.60.

Insiders Place Their Bets

In related news, Director David Weill purchased 1,336 shares of TransMedics Group stock in a transaction dated Friday, September 11th. The stock was bought at an average cost of $81.63 per share, for a total transaction of $109,057.68. Following the transaction, the director owned 16,392 shares in the company, valued at approximately $1,338,078.96. The trade was a 8.87% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 6.90% of the company's stock.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical technology company focused on improving organ transplantation through systems that preserve and assess donor organs outside the body. The company's primary platform is the Organ Care System (OCS), a portable, technology-enabled perfusion system designed to maintain organs in a functioning, near-physiologic state during transport and evaluation.

TransMedics offers OCS products for heart, lung and liver transplantation. Its systems are intended to support the use of organs that may not otherwise be suitable for conventional cold-storage methods, potentially expanding the donor pool and providing transplant teams with additional information when evaluating organs for transplantation.

Founded in 1998 and headquartered in Andover, Massachusetts, TransMedics serves transplant centers in the United States and select international markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.